<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:32:01Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:2394451" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:2394451</identifier><datestamp>2009-09-10</datestamp><setSpec>brjcancer</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://dtd.nlm.nih.gov/ns/archiving/2.3/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://dtd.nlm.nih.gov/ns/archiving/2.3/ https://dtd.nlm.nih.gov/archiving/2.3/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
      <journal-title>British Journal of Cancer</journal-title>
      <issn pub-type="ppub">0007-0920</issn>
      <issn pub-type="epub">1532-1827</issn>
      <publisher>
        <publisher-name>Nature Publishing Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC2394451</article-id>
      <article-id pub-id-type="pmcid">PMC2394451</article-id>
      <article-id pub-id-type="pmc-uid">2394451</article-id>
      <article-id pub-id-type="pmid">14612911</article-id>
      <article-id pub-id-type="pii">6601425</article-id>
      <article-id pub-id-type="doi">10.1038/sj.bjc.6601425</article-id>
      <article-id pub-id-type="pmid">14612911</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Genetics and Genomics</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>CHEK2</italic> variants associate with hereditary prostate cancer</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>SeppÃ¤lÃ¤</surname>
            <given-names>E H</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ikonen</surname>
            <given-names>T</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mononen</surname>
            <given-names>N</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Autio</surname>
            <given-names>V</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>RÃ¶kman</surname>
            <given-names>A</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matikainen</surname>
            <given-names>M P</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tammela</surname>
            <given-names>T L J</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schleutker</surname>
            <given-names>J</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="caf1">*</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label><sup>1</sup>Laboratory of Cancer Genetics, Institute of Medical Technology, LenkkeilijÃ¤nkatu 8,University of Tampere and Tampere University Hospital, FIN-33014 University of Tampere, Finland</aff>
      <aff id="aff2"><label>2</label><sup>2</sup>Research Unit, Tampere University Hospital, FIN-33521 Tampere, Finland</aff>
      <aff id="aff3"><label>3</label><sup>3</sup>Department of Urology, Tampere University Hospital and Medical School, University of Tampere, FIN-33521 Tampere, Finland</aff>
      <author-notes>
        <corresp id="caf1"><label>*</label>Author for correspondence: <email xlink:href="mailto:johanna.schleutker@uta.fi">johanna.schleutker@uta.fi</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>11</month>
        <year>2003</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>17</day>
        <month>11</month>
        <year>2003</year>
      </pub-date>
      <volume>89</volume>
      <issue>10</issue>
      <fpage>1966</fpage>
      <lpage>1970</lpage>
      <history>
        <date date-type="received">
          <day>08</day>
          <month>05</month>
          <year>2003</year>
        </date>
        <date date-type="rev-recd">
          <day>09</day>
          <month>08</month>
          <year>2003</year>
        </date>
        <date date-type="accepted">
          <day>20</day>
          <month>09</month>
          <year>2003</year>
        </date>
      </history>
      <copyright-statement>Copyright 2003, Cancer Research UK</copyright-statement>
      <copyright-year>2003</copyright-year>
      <permissions>
        <copyright-holder>Cancer Research UK</copyright-holder>
      </permissions>
      <kwd-group>
        <kwd>prostate cancer</kwd>
        <kwd>checkpoint</kwd>
        <kwd>CHEK2</kwd>
        <kwd>1100delC</kwd>
        <kwd>I157T</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Analyses using families with hereditary prostate cancer (HPC) have suggested that multiple genetic loci may harbour prostate cancer susceptibility genes, including HPC1 (MIM 601518) at 1q24âq25, HPC2 (MIM 605367) at 17p11, PCAP (MIM 602759) at 1q42âq43, HPCX (MIM 300147) at Xq27âq28, CAPB (MIM 603688) at 1p36, and HPC20 (MIM 176807) at 20q13 (<xref ref-type="other" rid="bib9">Nwosu <italic>et al</italic>, 2001</xref>). So far, only two genes have been identified from these chromosomal regions: <italic>ELAC2</italic> from HPC2 âlocus (<xref ref-type="other" rid="bib19">Tavtigian <italic>et al</italic>, 2001</xref>) and <italic>RNASEL</italic> (MIM 180435) from HPC1 âlocus (<xref ref-type="other" rid="bib3">Carpten <italic>et al</italic>, 2002</xref>). In Finland neither <italic>ELAC2</italic> nor <italic>RNASEL</italic> did explain the disease segregation in HPC families, but seemed to have some kind of modifying role in prostate carcinogenesis (<xref ref-type="other" rid="bib11">Rokman <italic>et al</italic>, 2001</xref>; <xref ref-type="other" rid="bib12">Rokman <italic>et al</italic>, 2002</xref>). <xref ref-type="other" rid="bib22">Xu <italic>et al</italic> (2001)</xref> identified a new locus at 8p22â23, and mutations in <italic>MSR1</italic> gene (MIM 153622) were reported to associate with prostate cancer (<xref ref-type="other" rid="bib23">Xu <italic>et al</italic>, 2002</xref>). However, recent results do not support a major role for the <italic>MSR1</italic> gene in the causation of prostate cancer (<xref ref-type="other" rid="bib16">Seppala <italic>et al</italic>, in press</xref>). Definitive confirmations of the role of <italic>ELAC2</italic>, <italic>RNASEL</italic>, or <italic>MSR1</italic> in prostate cancer predisposition are still warranted.</p>
    <p>Recently, mutations in <italic>CHEK2</italic> (MIM 604373) were identified in patients with prostate cancer (<xref ref-type="other" rid="bib4">Dong <italic>et al</italic>, 2003</xref>). The <italic>CHEK2</italic> gene localises to chromosome 22q12.1 and contains 14 exons. Originally, germline mutations in <italic>CHEK2</italic> gene were reported in LiâFraumeni syndrome and breast cancer (<xref ref-type="other" rid="bib2">Bell <italic>et al</italic>, 1999</xref>; <xref ref-type="other" rid="bib1">Allinen <italic>et al</italic>, 2001</xref>). Rare somatic mutations in <italic>CHEK2</italic> have also been identified in a number of cancer types, including lung and ovarian cancers and osteosarcomas (<xref ref-type="other" rid="bib8">Miller <italic>et al</italic>, 2002</xref>). These results together with the normal function of <italic>CHEK2</italic> in DNA damage checkpoints are consistent with the idea that <italic>CHEK2</italic> might act as a tumour suppressor gene. Here, we explored the significance of <italic>CHEK2</italic> gene in prostate cancer causation in Finland. The Finnish population is known to be historically isolated and genetically homogeneous (<xref ref-type="other" rid="bib10">Peltonen <italic>et al</italic>, 2000</xref>). Therefore, there may be a limited number of prostate cancer causing mutations, and the effect of individual risk genes could be identified more readily than in more heterogeneous populations.</p>
    <sec sec-type="materials|methods">
      <title>MATERIALS AND METHODS</title>
      <sec>
        <title>Families with HPC</title>
        <p>Collection of Finnish families with HPC has been described elsewhere (<xref ref-type="other" rid="bib14">Schleutker <italic>et al</italic>, 2000</xref>). For single-strand conformation polymorphism (SSCP) analysis, youngest affected patient from each of the 120 HPC families was initially used for the screening of <italic>CHEK2</italic> mutations. The HPC families consisted of two cohorts. The families in the first cohort (<italic>n</italic>=68) had either three or more first- or second-degree- affected members or two affected members with at least the index patient diagnosed with prostate cancer â©½60 years of age. The mean age at diagnosis for the index patients was 62.2 years (range 44â81 years), and the mean number of affected family members was 3.2 (range 2â6). The second cohort of families (<italic>n</italic>=52) had only two first- or second-degree affected members with ages at diagnosis &gt;60 years. The mean age at diagnosis for the index patients was 69.0 years (range 61â86).</p>
      </sec>
      <sec>
        <title>Patients with prostate cancer and controls</title>
        <p>The 1100delC and I157T variants were analysed in 537 patients with unselected prostate cancer, and in 480 healthy male blood donors. There were altogether 634 consecutive patients diagnosed with prostate cancer in the Pirkanmaa Hospital District with a population of around 450â000 during 1999â2000. We had samples from 85% of these patients, which results in an unselected, population-based collection of patients. The mean age at diagnosis for the patients with unselected prostate cancer was 68.6 years (range 47â90). Information was available on the tumour WHO-grade in 96%, on Gleason score in 88%, on T-stage in 100%, and on N-stage in 30% of the patients. M-stage was ascertained by bone scan in 73% of the patients with PSAâ©¾10â<italic>Î¼</italic>gâl<sup>â1</sup> and in 26% of the patients with PSA&lt;10â<italic>Î¼</italic>gâl<sup>â1</sup>. In all, 12% (66 out of 537) of the patients reported a positive family history of prostate cancer. The controls consisted of DNA samples from anonymous male blood donors obtained from the Blood Center of the Finnish Red Cross in Tampere.</p>
        <p>Written informed consent was obtained from all living patients and also, for families with HPC, from the unaffected members. The research protocols were approved by the Ethical Committee of the Tampere University Hospital (93175, 95062, and 99228), and the National Human Genome Research Institute (HG-0158). Permission for collection of families, in the entirety of Finland, was granted by the Ministry of Health and Social Affairs (59/08/95).</p>
      </sec>
      <sec>
        <title>Mutation screening with SSCP analysis</title>
        <p>Single-strand conformation polymorphism analysis of the entire coding sequence of the <italic>CHEK2</italic> gene was designed to include all intronâexon boundaries (GenBank accession number AF086904). Primers used for amplification of exons 10â14, which are known to be repeated on several other chromosomes (<xref ref-type="other" rid="bib17">Sodha <italic>et al</italic>, 2000</xref>), were designed so that both primers for each primer pair had a base mismatch in the most 3â² nucleotide, compared with sequences from nonfunctional copies of <italic>CHEK2</italic>. Genomic DNA was used at 25âng per 15â<italic>Î¼</italic>l reaction mixture containing 1.5âm<sc>M</sc> MgCl<sub>2</sub>; 20â<italic>Î¼</italic><sc>M</sc> each of dNTP; 0.5â<italic>Î¼</italic>Ci of <italic>Î±</italic>(<sup>33</sup>P)-dCTP (Amersham Pharmacia, Uppsala, Sweden); 0.6â<italic>Î¼</italic><sc>M</sc> of each primer; 1.0âU Ampli<italic>Taq</italic>Gold; and the reaction buffer provided by the supplier (PE Biosystems, Foster City, CA, USA). Annealing temperature of 50Â°C (for exons 10 and 12) or 55Â°C (for all other exons) was used. After denaturation, the (<sup>33</sup>P)-labeled PCR products were electrophoresed at 800âV for 12âh at room temperature, in 0.5 Ã mutation-detection-enhancement gel (FMC BioProducts, Rockland, ME, USA) with 1% glycerol in 0.5 Ã Tris-borate EDTA. For exon 11, the electrophoresis was also performed without glycerol in the gel. After electrophoresis, gels were dried and exposed to Kodak BioMax maximum-resolution films for 6âh. All samples, in which variant bands were detected, as well as two normal bands per exon, were sequenced using the same PCR primers and ABI Prism 310 Genetic Analyzer (PE Biosystems, Foster City, CA, USA). Also, the genotypes of the available family members of the mutation carriers were determined by sequencing.</p>
      </sec>
      <sec>
        <title>Minisequencing and SSCP for large-scale population screening of identified variants</title>
        <p>The frequencies of the two <italic>CHEK2</italic> variants were determined in the entire sample of patients described above. 1100delC variant was screened by minisequencing (<xref ref-type="other" rid="bib18">Syvanen, 1998</xref>). PCR was performed with 100âng of DNA, 0.2â<italic>Î¼</italic><sc>M</sc> each primer, 0.2âm<sc>M</sc> each dNTP, 1.5âm<sc>M</sc> MgCl<sub>2</sub>, and 1.0âU of Ampli<italic>Taq</italic>Gold (PE Biosystems, Foster City, CA, USA), in a final volume of 50â<italic>Î¼</italic>l. I157T variant was screened by SSCP analysis as described above. Positive results from both mutation analyses were confirmed by sequencing.</p>
      </sec>
      <sec>
        <title>Statistical analyses</title>
        <p>Association of the CHEK2 genotypes with HPC and unselected prostate cancer was tested by logistic-regression analysis, by use of the SPSS statistical software package (SPSS 11.0). Association with demographic, clinical, and pathological features of the disease was tested by the MannâWhitney test, Pearson <italic>Ï</italic><sup>2</sup> test, and Fisher's exact test by use of the SPSS statistical software package (SPSS 11.0).</p>
      </sec>
    </sec>
    <sec>
      <title>RESULTS</title>
      <p>Five sequence variants were identified in the SSCP analysis of the <italic>CHEK2</italic> gene in 120 index patients from Finnish families with HPC (<xref rid="tbl1" ref-type="table">Table 1</xref>
 <table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Summary of <italic>CHEK2</italic> germline variants found in 120 patients with HPC in the SSCP analysis</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Mutation</bold></th><th align="left" valign="top" charoff="50"><bold>Amino-acid change</bold></th><th align="left" valign="top" charoff="50"><bold>Exon/intron</bold></th><th align="left" valign="top" charoff="50"><bold>Domain</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">252A&gt;G</td><td align="left" valign="top" charoff="50">Silent (E84)</td><td align="left" valign="top" charoff="50">Exon 1</td><td align="left" valign="top" charoff="50">Unknown</td></tr><tr><td align="left" valign="top" charoff="50">319+(43â44)insA</td><td align="left" valign="top" charoff="50">â</td><td align="left" valign="top" charoff="50">Intron1</td><td align="left" valign="top" charoff="50">â</td></tr><tr><td align="left" valign="top" charoff="50">470T&gt;C</td><td align="left" valign="top" charoff="50">I157T</td><td align="left" valign="top" charoff="50">Exon 3</td><td align="left" valign="top" charoff="50">FHA<sup>a</sup></td></tr><tr><td align="left" valign="top" charoff="50">1100delC</td><td align="left" valign="top" charoff="50">Frameshift</td><td align="left" valign="top" charoff="50">Exon 10</td><td align="left" valign="top" charoff="50">Kinase</td></tr><tr><td align="left" valign="top" charoff="50">1312G&gt;T</td><td align="left" valign="top" charoff="50">D438Y</td><td align="left" valign="top" charoff="50">Exon 11</td><td align="left" valign="top" charoff="50">Kinase</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label>a</label><p>FHA=forkhead-associated domain.</p></fn></table-wrap-foot></table-wrap>). Two of the variants, a missense variant 470T&gt;C (I157T) in exon 3 and a frameshift mutation 1100delC in exon 10, were the same as previously reported in patients with LiâFraumeni syndrome (<xref ref-type="other" rid="bib2">Bell <italic>et al</italic>, 1999</xref>), breast (<xref ref-type="other" rid="bib1">Allinen <italic>et al</italic>, 2001</xref>; <xref ref-type="other" rid="bib20">Vahteristo <italic>et al</italic>, 2002</xref>), and prostate cancer (<xref ref-type="other" rid="bib4">Dong <italic>et al</italic>, 2003</xref>). The frameshift 1100delC mutation has been proven to result in the loss of kinase activity (<xref ref-type="other" rid="bib21">Wu <italic>et al</italic>, 2001</xref>), and I157T variant has been shown to be defective in its ability to bind and phosphorylate Cdc25A, one of its normal substrates (<xref ref-type="other" rid="bib5">Falck <italic>et al</italic>, 2001</xref>). These variants were further studied in a set of 1137 samples. In addition, a silent exonic change also reported by <xref ref-type="other" rid="bib2">Bell <italic>et al</italic> (1999)</xref>, an intronic change (not affecting splice site), and a novel missense mutation 1312G&gt;T (D438Y) were observed. D438Y mutation was found only in one proband. In this family there were two prostate cancer patients. Unfortunately, we did not have a sample from the second affected person (deceased).</p>
      <p>The 120 patients with HPC included 3.3% (four out of 120) patients who carried the 1100delC mutation (<xref rid="tbl2" ref-type="table">Table 2</xref>
 <table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p content-type="table-title">Association of the 1100delC and I157T variants of the <italic>CHEK2</italic> gene with patients with unselected prostate cancer or HPC</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Mutation and sample</bold></th><th align="char" valign="top" char="." charoff="50"><bold>No. of carriers/total (frequency)</bold></th><th align="char" valign="top" char="." charoff="50"><bold>OR</bold></th><th align="left" valign="top" charoff="50"><bold>95% CI</bold></th><th align="left" valign="top" charoff="50"><bold><italic>P</italic></bold></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>1100delC</italic></td></tr><tr><td align="left" valign="top" charoff="50">âControls</td><td align="char" valign="top" char="." charoff="50">2/480 (0.4%)</td><td align="char" valign="top" char="." charoff="50">1.00</td><td align="left" valign="top" charoff="50">Â </td><td align="left" valign="top" charoff="50">Â </td></tr><tr><td align="left" valign="top" charoff="50">âPatients with unselected âProstate cancer</td><td align="char" valign="top" char="." charoff="50">7/537 (1.3%)</td><td align="char" valign="top" char="." charoff="50">3.14</td><td align="char" valign="top" char="." charoff="50">0.65â15.16</td><td align="char" valign="top" char="." charoff="50">0.15</td></tr><tr><td align="left" valign="top" charoff="50">âPatients with HPC</td><td align="char" valign="top" char="." charoff="50">4/120 (3.3%)</td><td align="char" valign="top" char="." charoff="50">8.24</td><td align="char" valign="top" char="." charoff="50">1.49â45.54</td><td align="char" valign="top" char="." charoff="50">0.02<sup>a</sup></td></tr><tr><td align="left" valign="top" charoff="50">Â </td><td align="char" valign="top" char="." charoff="50">Â </td><td align="char" valign="top" char="." charoff="50">Â </td><td align="left" valign="top" charoff="50">Â </td><td align="left" valign="top" charoff="50">Â </td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>I157T</italic></td></tr><tr><td align="left" valign="top" charoff="50">âControls</td><td align="char" valign="top" char="." charoff="50">26/480 (5.4%)</td><td align="char" valign="top" char="." charoff="50">1.00</td><td align="left" valign="top" charoff="50">Â </td><td align="left" valign="top" charoff="50">Â </td></tr><tr><td align="left" valign="top" charoff="50">âPatients with unselected âProstate cancer</td><td align="char" valign="top" char="." charoff="50">42/537 (7.8%)</td><td align="char" valign="top" char="." charoff="50">1.48</td><td align="char" valign="top" char="." charoff="50">0.89â2.46</td><td align="char" valign="top" char="." charoff="50">0.13</td></tr><tr><td align="left" valign="top" charoff="50">âPatients with HPC</td><td align="char" valign="top" char="." charoff="50">13/120 (10.8%)</td><td align="char" valign="top" char="." charoff="50">2.12</td><td align="char" valign="top" char="." charoff="50">1.06â4.27</td><td align="char" valign="top" char="." charoff="50">0.04<sup>a</sup></td></tr></tbody></table><table-wrap-foot><fn id="tbfnote2"><label>a</label><p>Statistically significant.</p></fn></table-wrap-foot></table-wrap>). This was significantly higher (odds ratio (OR)=8.24; 95% confidence interval (CI) 1.49â45.54; <italic>P</italic>=0.02) than the frequency 0.4% seen in population sample of 480 blood donors. Among the unselected patients with prostate cancer, the frequency of 1100delC variant was 1.3% (seven out of 537). All 1100delC carriers were heterozygous. All other affected and unaffected male relatives were also genotyped from 1100delC-positive families. Suggestive evidence of segregation between the 1100delC mutation and prostate cancer was seen in all four families (<xref ref-type="fig" rid="fig1">Figure 1</xref><fig id="fig1"><label>Figure 1</label><caption><p>Segregation of <italic>CHEK2</italic> 1100delC mutation in four families with HPC. 1100delC variant carriers are denoted by a plus sign (+), and noncarriers by a minus sign (â). An asterisk (<sup>*</sup>)) denotes the persons with no sample available. No sample was available from affected father (II-2) in family 351, but because the mother (II-1) did not carry the mutation, the father is a likely 1100delC mutation carrier. Current age of the unaffected members or age at diagnosis for prostate cancer patients (in years) is indicated below the symbol for each family member. In each family, the index patient is marked with an arrow. Squares denote male subjects, and circles denote female subjects; black symbols denote patients with prostate cancer.</p></caption><graphic mime-subtype="gif" xlink:href="89-6601425f1"/></fig>). Since 1100delC mutation has been reported in LiâFraumeni syndrome and was previously called a mutation hot spot (<italic>CHEK2</italic> [MIM 604373]), we looked other cancers in these four 1100delC-positive families. In family 001, there was one second-degree relative diagnosed with lung cancer, but no other cancers were found among first- or second-degree relatives.</p>
      <p>The I157T variant was seen in 10.8% (13 out of 120) of patients with HPC (<xref rid="tbl2" ref-type="table">Table 2</xref>). This was also significantly higher (OR=2.12; 95% CI 1.06â4.27; <italic>P</italic>=0.04) than the frequency of 5.4% seen in the population controls. Nine of the I157T-positive families had only two affecteds, three families had three affecteds, and one family had four affecteds. Segregation of the variant with the disease was incomplete, in that both unaffected mutation carriers and mutation-negative patients with prostate cancer were observed. In addition, the I157T variant was found in 7.8% (42 out of 537) of unselected prostate cancer patients. One of these carriers was homozygous; all other I157T variant carriers were heterozygous. The homozygous carrier did not have family history of cancer and there was nothing unusual in his phenotype. None of the patients or controls carried both 1100delC and I157T variant.</p>
      <p>The mean ages at diagnosis of the <italic>CHEK2</italic> variant carriers in patients with HPC were 62.7 years for 1100delC carriers and 64.0 years for I157T carriers. These ages were only marginally different from the mean age of HPC patients with no mutations (65.2 years for both variants; <italic>P</italic>=0.57 for 1100delC and <italic>P</italic>=0.62 for I157T). A similar trend was observed in the cohort of unselected prostate cancer patients (64.6 <italic>vs</italic> 68.7 years; <italic>P</italic>=0.18 for 1100delC and 68.4 <italic>vs</italic> 68.6 years; <italic>P</italic>=0.86 for I157T). The association between the frequency of the two variants and disease phenotype, including tumour WHO-grade, Gleason score, T-, N- and M-stage and PSA value at diagnosis, were also analysed among unselected prostate cancer cases. No significant associations emerged from these analyses (data not shown).</p>
    </sec>
    <sec>
      <title>DISCUSSION</title>
      <p><italic>CHEK2</italic> has been suggested to be a candidate tumour suppressor gene on the basis of the findings that normal function of CHEK2 is involved in DNA-damage respond and some of the mutations identified in LiâFraumeni families were expected to result in a truncated protein (<xref ref-type="other" rid="bib2">Bell <italic>et al</italic>, 1999</xref>). Subsequently, these findings were supported by the reports concerning identical and additional mutations in patients with LiâFraumeni syndrome (<xref ref-type="other" rid="bib6">Lee <italic>et al</italic>, 2001</xref>) and breast cancer (<xref ref-type="other" rid="bib7">Meijers-Heijboer <italic>et al</italic>, 2002</xref>; <xref ref-type="other" rid="bib20">Vahteristo <italic>et al</italic>, 2002</xref>). While this manuscript was in preparation, another study was published showing that mutations in <italic>CHEK2</italic> were associated also with prostate cancer risk (<xref ref-type="other" rid="bib4">Dong <italic>et al</italic>, 2003</xref>).</p>
      <p>Our results suggest that <italic>CHEK2</italic> 1100delC mutation is associated with positive family history of prostate cancer. The mutation segregated almost completely in all mutation-positive families (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In family 351, there were three unaffected men, who carried the variant. Two of them were rather young, about 50 years old (III-2 and III-3), and the third unaffected carrier was 71 years old (II-5). The total PSA values of the unaffected mutation carriers of this family were measured in July 2000. The values were &lt;0.5, 2.2, and 2.4â<italic>Î¼</italic>gâl<sup>â1</sup> for III-2, III-3 and II-5, respectively. The mean age at diagnosis of prostate cancer in Finland was 71.1 years in 1999 (Finnish Cancer Registry; cancer statistics at
 <ext-link ext-link-type="uri" xlink:href="http://www.cancerregistry.fi/">http://www.cancerregistry.fi/</ext-link>) and all three affecteds of the family 351 were over 66 years old when diagnosed for prostate cancer, thus the future diagnosis of prostate cancer cannot be ruled out for the healthy carriers of this family. On the other hand, in the four 1100delC-positive families, there were no mutation-negative prostate cancer patients. The association of 1100delC mutation with families that include small number of affected relatives, the most common types of prostate cancer families, implies that the mutation is likely to have a significant contribution to familial prostate cancer at the population level. In addition, I157T seems to be a disease-associated polymorphism at least in the Finnish population. It has a slightly higher frequency among patients with unselected prostate cancer than among control individuals and it is strongly associated with family history of the disease. However, according to the previous reports, the I157T allele does not make a significant contribution to breast cancer susceptibility (<xref ref-type="other" rid="bib1">Allinen <italic>et al</italic>, 2001</xref>; <xref ref-type="other" rid="bib15">Schutte <italic>et al</italic>, 2003</xref>). Therefore, the association with this allele is less conclusive.</p>
      <p>Previously, <xref ref-type="other" rid="bib20">Vahteristo <italic>et al</italic> (2002)</xref> reported the strong association of the <italic>CHEK2</italic> 1100delC with breast cancer families that included only two affected patients, suggesting that 1100delC is a low-penetrance genetic alteration. In contrast to our results, <xref ref-type="other" rid="bib4">Dong <italic>et al</italic> (2003)</xref> reported the association of the <italic>CHEK2</italic> mutations (all mutations pooled together) only with sporadic prostate cancer. In addition, they did not observe any association between prostate cancer and I157T variant. The reason why <xref ref-type="other" rid="bib4">Dong <italic>et al</italic> (2003)</xref> did not detect any association with HPC could be due to different sample settings: the families from the USA represent more extreme HPC families than the Finnish families in the present study. In their study two affected members from 149 HPC families with at minimum of three affected men over at least two generations were used. In our recent genome-wide linkage analysis, no positive signals were seen on chromosome 22 (<xref ref-type="other" rid="bib13">Schleutker <italic>et al</italic>, in press</xref>). This is probably due to the selected study material, as only the most extreme families were genotyped, possibly reflecting the same phenomenon as seen in the study of <xref ref-type="other" rid="bib4">Dong <italic>et al</italic> (2003)</xref>. Also, the low allele frequencies of <italic>CHEK2</italic> variants (&lt;10%) make this kind of an association almost impossible to detect by linkage analysis.</p>
      <p><xref ref-type="other" rid="bib4">Dong <italic>et al</italic> (2003)</xref> reported a total of 13 different <italic>CHEK2</italic> germline mutations among 400 sporadic prostate cancer patients and 298 individuals with familial prostate cancer. Most of these mutations occurred only once in their study population. The reason why fewer variants were found in our study can possibly be due to the limited sensitivity of the SSCP analysis and the number of screened patients. Most likely, however, the reason is the study population itself. The Finnish population is genetically much more homogeneous than the US population, and therefore it is not surprising that fewer variants were detected.</p>
      <p>Taken together, finding of the 1100delC and I157T variants in families with small numbers of affected relatives support the idea that <italic>CHEK2</italic> variants are low-penetrance prostate cancer predisposition alleles that contribute significantly to familial clustering of prostate cancer at the population level, especially in families with small number of affected relatives. However, variants in <italic>CHEK2</italic> gene alone do not explain the familial clustering of prostate cancer in Finland as the majority of families did not have any <italic>CHEK2</italic> alterations. The present results warrant further studies of the role of <italic>CHEK2</italic> variants as a risk factor for prostate cancer in other populations.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We thank Minna SjÃ¶blom and Riitta Vaalavuo for excellent technical assistance. The prostate cancer patients and their families are thanked for their participation and cooperation. This study was supported by the Medical Research Foundation of Tampere University Hospital, the Reino Lahtikari Foundation the Finnish Cancer Organisations, the Sigrid Juselius Foundation and the Academy of Finland. EHS received support from Pirkanmaa Cancer Society and from the University of Tampere.</p>
    </ack>
    <ref-list>
      <ref id="bib1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Allinen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Huusko</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mantyniemi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Launonen</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Winqvist</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Mutation analysis of the CHK2 gene in families with hereditary breast cancer</article-title>
          <source>Br J Cancer</source>
          <year>2001</year>
          <volume>85</volume>
          <fpage>209</fpage>
          <lpage>212</lpage>
          <!--PubMed citation query: 'Br J Cancer||85|209||bib1|'-->
          <pub-id pub-id-type="pmid">11461078</pub-id>
        </citation>
      </ref>
      <ref id="bib2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bell</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Varley</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Szydlo</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Kang</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Wahrer</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Lubratovich</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Verselis</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Isselbacher</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Fraumeni</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Birch</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>FP</given-names>
            </name>
            <name>
              <surname>Garber</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Haber</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Heterozygous germ line hCHK2 mutations in LiâFraumenisyndrome</article-title>
          <source>Science</source>
          <year>1999</year>
          <volume>286</volume>
          <fpage>2528</fpage>
          <lpage>2531</lpage>
          <!--PubMed citation query: 'Science||286|2528||bib2|'-->
          <pub-id pub-id-type="pmid">10617473</pub-id>
        </citation>
      </ref>
      <ref id="bib3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carpten</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nupponen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Isaacs</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sood</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Robbins</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Faruque</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Moses</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ewing</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gillanders</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bujnovszky</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Makalowska</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Baffoe-Bonnie</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Faith</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stephan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wiley</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Brownstein</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gildea</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Jenkins</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hostetter</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Matikainen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schleutker</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Klinger</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Connors</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Xiang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>De Marzo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Papadopoulos</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kallioniemi</surname>
              <given-names>OP</given-names>
            </name>
            <name>
              <surname>Burk</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Meyers</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gronberg</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Meltzer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Silverman</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bailey-Wilson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Isaacs</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Trent</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Germline mutations in the ribonuclease L gene in families showing linkage with HPC1</article-title>
          <source>Nat Genet</source>
          <year>2002</year>
          <volume>30</volume>
          <fpage>181</fpage>
          <lpage>184</lpage>
          <!--PubMed citation query: 'Nat Genet||30|181||bib3|'-->
          <pub-id pub-id-type="pmid">11799394</pub-id>
        </citation>
      </ref>
      <ref id="bib4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dong</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Taniguchi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Cunningham</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>McDonnell</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Qian</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Marks</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Slager</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>DI</given-names>
            </name>
            <name>
              <surname>Cheville</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Blute</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Schaid</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Tindall</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Thibodeau</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Mutations in CHEK2 associated with prostate cancer risk</article-title>
          <source>Am J Hum Genet</source>
          <year>2003</year>
          <volume>72</volume>
          <fpage>270</fpage>
          <lpage>280</lpage>
          <!--PubMed citation query: 'Am J Hum Genet||72|270||bib4|'-->
          <pub-id pub-id-type="pmid">12533788</pub-id>
        </citation>
      </ref>
      <ref id="bib5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Falck</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mailand</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Syljuasen</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Bartek</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lukas</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis</article-title>
          <source>Nature</source>
          <year>2001</year>
          <volume>410</volume>
          <fpage>842</fpage>
          <lpage>847</lpage>
          <!--PubMed citation query: 'Nature||410|842||bib5|'-->
          <pub-id pub-id-type="pmid">11298456</pub-id>
        </citation>
      </ref>
      <ref id="bib6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Wahrer</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Schiripo</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Jorczak</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Sgroi</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Garber</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>FP</given-names>
            </name>
            <name>
              <surname>Nichols</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Varley</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Godwin</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Shannon</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Harlow</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Haber</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Destabilization of CHK2 by a missense mutation associated with LiâFraumeni Syndrome</article-title>
          <source>Cancer Res</source>
          <year>2001</year>
          <volume>61</volume>
          <fpage>8062</fpage>
          <lpage>8067</lpage>
          <!--PubMed citation query: 'Cancer Res||61|8062||bib6|'-->
          <pub-id pub-id-type="pmid">11719428</pub-id>
        </citation>
      </ref>
      <ref id="bib7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meijers-Heijboer</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>van den Ouweland</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Klijn</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wasielewski</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>de Snoo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Oldenburg</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hollestelle</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Houben</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Crepin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>van Veghel-Plandsoen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Elstrodt</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>van Duijn</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bartels</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Meijers</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schutte</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>McGuffog</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Easton</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sodha</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Seal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Barfoot</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mangion</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chang-Claude</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Eccles</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Eeles</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Houlston</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Murday</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Narod</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Peretz</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Peto</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Phelan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>HX</given-names>
            </name>
            <name>
              <surname>Szabo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Devilee</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Goldgar</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Futreal</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Nathanson</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rahman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Stratton</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Low-penetrance susceptibility to breast cancer due to CHEK2(<sup>*</sup>)1100delC in noncarriers of BRCA1 or BRCA2 mutations</article-title>
          <source>Nat Genet</source>
          <year>2002</year>
          <volume>31</volume>
          <fpage>55</fpage>
          <lpage>59</lpage>
          <!--PubMed citation query: 'Nat Genet||31|55||bib7|'-->
          <pub-id pub-id-type="pmid">11967536</pub-id>
        </citation>
      </ref>
      <ref id="bib8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miller</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Ikezoe</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Krug</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Hofmann</surname>
              <given-names>WK</given-names>
            </name>
            <name>
              <surname>Tavor</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vegesna</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Tsukasaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Takeuchi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Koeffler</surname>
              <given-names>HP</given-names>
            </name>
          </person-group>
          <article-title>Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors</article-title>
          <source>Genes Chromosomes Cancer</source>
          <year>2002</year>
          <volume>33</volume>
          <fpage>17</fpage>
          <lpage>21</lpage>
          <!--PubMed citation query: 'Genes Chromosomes Cancer||33|17||bib8|'-->
          <pub-id pub-id-type="pmid">11746983</pub-id>
        </citation>
      </ref>
      <ref id="bib9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nwosu</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Carpten</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Trent</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Sheridan</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease</article-title>
          <source>Hum Mol Genet</source>
          <year>2001</year>
          <volume>10</volume>
          <fpage>2313</fpage>
          <lpage>2318</lpage>
          <!--PubMed citation query: 'Hum Mol Genet||10|2313||bib9|'-->
          <pub-id pub-id-type="pmid">11673416</pub-id>
        </citation>
      </ref>
      <ref id="bib10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Peltonen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Palotie</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lange</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Use of population isolates for mapping complex traits</article-title>
          <source>Nat Rev Genet</source>
          <year>2000</year>
          <volume>1</volume>
          <fpage>182</fpage>
          <lpage>190</lpage>
          <!--PubMed citation query: 'Nat Rev Genet||1|182||bib10|'-->
          <pub-id pub-id-type="pmid">11252747</pub-id>
        </citation>
      </ref>
      <ref id="bib11">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rokman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ikonen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mononen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Autio</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Matikainen</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Koivisto</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Tammela</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Kallioniemi</surname>
              <given-names>OP</given-names>
            </name>
            <name>
              <surname>Schleutker</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer</article-title>
          <source>Cancer Res</source>
          <year>2001</year>
          <volume>61</volume>
          <fpage>6038</fpage>
          <lpage>6041</lpage>
          <!--PubMed citation query: 'Cancer Res||61|6038||bib11|'-->
          <pub-id pub-id-type="pmid">11507049</pub-id>
        </citation>
      </ref>
      <ref id="bib12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rokman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ikonen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Seppala</surname>
              <given-names>EH</given-names>
            </name>
            <name>
              <surname>Nupponen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Autio</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Mononen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bailey-Wilson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Trent</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Carpten</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Matikainen</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Koivisto</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Tammela</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Kallioniemi</surname>
              <given-names>OP</given-names>
            </name>
            <name>
              <surname>Schleutker</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer</article-title>
          <source>Am J Hum Genet</source>
          <year>2002</year>
          <volume>70</volume>
          <fpage>1299</fpage>
          <lpage>1304</lpage>
          <!--PubMed citation query: 'Am J Hum Genet||70|1299||bib12|'-->
          <pub-id pub-id-type="pmid">11941539</pub-id>
        </citation>
      </ref>
      <ref id="bib13">
        <citation citation-type="other"><person-group person-group-type="author"><name><surname>Schleutker</surname><given-names>J</given-names></name><name><surname>Baffoe-Bonnie</surname><given-names>A</given-names></name><name><surname>Gillanders</surname><given-names>E</given-names></name><name><surname>Kainu</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>MP</given-names></name><name><surname>Gildea</surname><given-names>D</given-names></name><name><surname>Riedesel</surname><given-names>E</given-names></name><name><surname>Albertus</surname><given-names>J</given-names></name><name><surname>Freas-Lutz</surname><given-names>D</given-names></name><name><surname>Markey</surname><given-names>C</given-names></name><name><surname>Gibbs</surname><given-names>KD</given-names></name><name><surname>Matikainen</surname><given-names>M</given-names></name><name><surname>Koivisto</surname><given-names>P</given-names></name><name><surname>Tammela</surname><given-names>T</given-names></name><name><surname>Bailey-Wilson</surname><given-names>J</given-names></name><name><surname>Trent</surname><given-names>J</given-names></name><name><surname>Kallioniemi</surname><given-names>OP</given-names></name></person-group><article-title>A genome-wide scan for linkage in Finnish hereditary prostate cancer (HPC) families identifies novel susceptibility loci at 11q14 and 3p25âp26</article-title><source>Prostate</source>Unpublished manuscript listed in Human Relations Area Files (HRAF) eHRAF collection of ethnography: a world of cultures at your fingertips. http://ets.umdl.umich.edu/e/chrafe</citation>
      </ref>
      <ref id="bib14">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schleutker</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Matikainen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Koivisto</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Baffoe-Bonnie</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kainu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gillanders</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Sankila</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pukkala</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Carpten</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stephan</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Tammela</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Brownstein</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bailey-Wilson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Trent</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kallioniemi</surname>
              <given-names>OP</given-names>
            </name>
          </person-group>
          <article-title>A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: frequent HPCX linkage in families with late-onset disease</article-title>
          <source>Clin Cancer Res</source>
          <year>2000</year>
          <volume>6</volume>
          <fpage>4810</fpage>
          <lpage>4815</lpage>
          <!--PubMed citation query: 'Clin Cancer Res||6|4810||bib14|'-->
          <pub-id pub-id-type="pmid">11156239</pub-id>
        </citation>
      </ref>
      <ref id="bib15">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schutte</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Seal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Barfoot</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Meijers-Heijboer</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wasielewski</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Evans</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Eccles</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Meijers</surname>
              <given-names>CFL</given-names>
            </name>
            <name>
              <surname>Klijn</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>van den Ouweland</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Consortium</surname>
              <given-names>TBCL</given-names>
            </name>
            <name>
              <surname>Futreal</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Nathanson</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Easton</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Stratton</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Rahman</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility</article-title>
          <source>Am J Hum Genet</source>
          <year>2003</year>
          <volume>72</volume>
          <fpage>1023</fpage>
          <lpage>1028</lpage>
          <!--PubMed citation query: 'Am J Hum Genet||72|1023||bib15|'-->
          <pub-id pub-id-type="pmid">12610780</pub-id>
        </citation>
      </ref>
      <ref id="bib16">
        <citation citation-type="other"><person-group person-group-type="author"><name><surname>Seppala</surname><given-names>EH</given-names></name><name><surname>Ikonen</surname><given-names>T</given-names></name><name><surname>Autio</surname><given-names>V</given-names></name><name><surname>Rokman</surname><given-names>A</given-names></name><name><surname>Mononen</surname><given-names>N</given-names></name><name><surname>Matikainen</surname><given-names>M</given-names></name><name><surname>Tammela</surname><given-names>T</given-names></name><name><surname>Schleutker</surname><given-names>J</given-names></name></person-group><article-title>Germline alterations in MSR1 gene and prostate cancer risk</article-title><source>Clin Cancer Res</source>in press</citation>
      </ref>
      <ref id="bib17">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sodha</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mangion</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bullock</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Yuille</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Eeles</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Screening hCHK2 for mutations</article-title>
          <source>Science</source>
          <year>2000</year>
          <volume>289</volume>
          <fpage>359</fpage>
          <!--PubMed citation query: 'Science||289|359||bib17|'-->
          <pub-id pub-id-type="pmid">10939935</pub-id>
        </citation>
      </ref>
      <ref id="bib18">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Syvanen</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title>Solid-phase minisequencing as a tool to detect DNA polymorphism</article-title>
          <source>Methods Mol Biol</source>
          <year>1998</year>
          <volume>98</volume>
          <fpage>291</fpage>
          <lpage>298</lpage>
          <!--PubMed citation query: 'Methods Mol Biol||98|291||bib18|'-->
          <pub-id pub-id-type="pmid">9664572</pub-id>
        </citation>
      </ref>
      <ref id="bib19">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tavtigian</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Simard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Teng</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Abtin</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Baumgard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Beck</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Camp</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Carillo</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Dayananth</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Desrochers</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dumont</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Farnham</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Frank</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Frye</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ghaffari</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gupte</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Iliev</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Janecki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kort</surname>
              <given-names>EN</given-names>
            </name>
            <name>
              <surname>Laity</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Leavitt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Leblanc</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>McArthur-Morrison</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pederson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Penn</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Richards</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schroeder</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Snyder</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Swedlund</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Swensen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tranchant</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Woodland</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Labrie</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Skolnick</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Neuhausen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rommens</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cannon-Albright</surname>
              <given-names>LA</given-names>
            </name>
          </person-group>
          <article-title>A candidate prostate cancer susceptibility gene at chromosome 17p</article-title>
          <source>Nat Genet</source>
          <year>2001</year>
          <volume>27</volume>
          <fpage>172</fpage>
          <lpage>180</lpage>
          <!--PubMed citation query: 'Nat Genet||27|172||bib19|'-->
          <pub-id pub-id-type="pmid">11175785</pub-id>
        </citation>
      </ref>
      <ref id="bib20">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vahteristo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bartkova</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Eerola</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Syrjakoski</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ojala</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kilpivaara</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Tamminen</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kononen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Aittomaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Heikkila</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Holli</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Blomqvist</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bartek</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kallioniemi</surname>
              <given-names>OP</given-names>
            </name>
            <name>
              <surname>Nevanlinna</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer</article-title>
          <source>Am J Hum Genet</source>
          <year>2002</year>
          <volume>71</volume>
          <fpage>432</fpage>
          <lpage>438</lpage>
          <!--PubMed citation query: 'Am J Hum Genet||71|432||bib20|'-->
          <pub-id pub-id-type="pmid">12094328</pub-id>
        </citation>
      </ref>
      <ref id="bib21">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Webster</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Characterization of tumor-associated Chk2 mutations</article-title>
          <source>J Biol Chem</source>
          <year>2001</year>
          <volume>276</volume>
          <fpage>2971</fpage>
          <lpage>2974</lpage>
          <!--PubMed citation query: 'J Biol Chem||276|2971||bib21|'-->
          <pub-id pub-id-type="pmid">11053450</pub-id>
        </citation>
      </ref>
      <ref id="bib22">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Hawkins</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Faith</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Isaacs</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Wiley</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ewing</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Bujnovszky</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Carpten</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Bleecker</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Trent</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Meyers</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Isaacs</surname>
              <given-names>WB</given-names>
            </name>
          </person-group>
          <article-title>Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23</article-title>
          <source>Am J Hum Genet</source>
          <year>2001</year>
          <volume>69</volume>
          <fpage>341</fpage>
          <lpage>350</lpage>
          <!--PubMed citation query: 'Am J Hum Genet||69|341||bib22|'-->
          <pub-id pub-id-type="pmid">11443539</pub-id>
        </citation>
      </ref>
      <ref id="bib23">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Komiya</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mychaleckyj</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Isaacs</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Sterling</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Lange</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Hawkins</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ewing</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Faith</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Suzuki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Bujnovszky</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wiley</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>DeMarzo</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Bova</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>McCullough</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Partin</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Kassabian</surname>
              <given-names>VS</given-names>
            </name>
            <name>
              <surname>Carpten</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Bailey-Wilson</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Trent</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Ohar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bleecker</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Isaacs</surname>
              <given-names>WB</given-names>
            </name>
            <name>
              <surname>Meyers</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk</article-title>
          <source>Nat Genet</source>
          <year>2002</year>
          <volume>32</volume>
          <fpage>321</fpage>
          <lpage>325</lpage>
          <!--PubMed citation query: 'Nat Genet||32|321||bib23|'-->
          <pub-id pub-id-type="pmid">12244320</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>